Presentation is loading. Please wait.

Presentation is loading. Please wait.

Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched.

Published byCarina Månsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched."— Presentation transcript:

1 Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation  Khilna Patel, Sapna Parmar, Shreya Shah, Tsiporah Shore, Usama Gergis, Sebastian Mayer, Koen van Besien  Biology of Blood and Marrow Transplantation  Volume 22, Issue 3, Pages (March 2016) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure 1 Treatment plan. Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan–Based Conditioning in Matched."

Similar presentations

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease  Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,

The Complex Relationship between Human Herpesvirus 6 and Acute Graft-versus-Host Disease  Claire Pichereau, Kristell Desseaux, Anne Janin, Catherine Scieux,
Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,

Topical Ruxolitinib Protects LGR5+ Stem Cells in the Hair Follicle and Ameliorates Skin Graft-Versus-Host Disease  Shuichiro Takahashi, MD, Daigo Hashimoto,
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Vaccination of Children following Allogeneic Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation
Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.
Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.

Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Allogeneic Stem Cell Transplantation in Myelofibrosis

Allogeneic Stem Cell Transplantation in Myelofibrosis
Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 

Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience 
Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation  Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,
Sabina Kersting, Leo F. Verdonck 

Sabina Kersting, Leo F. Verdonck 
A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation 
Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.

Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival  Mary.
Betty T. Tran, Abigail Halperin, Jason W. Chien 

Betty T. Tran, Abigail Halperin, Jason W. Chien 
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells.

Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells.
Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH 
Stephanie J. Lee, Loretta A. Williams 

Stephanie J. Lee, Loretta A. Williams 
Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)  Tania.

Outcomes with Pre-Emptive Rituximab (pre-R) Treatment for Epstein-Barr Viremia (EBV) after Allogeneic Hematopoietic Stem Cell Transplantation (HCT)  Tania.

Similar presentations

Ads by Google